Anticoagulation Collaborative Practice Agreement

What is known and objective is that optimal management of ambulatory anticoagulation requires a systematic and coordinated approach. Ample evidence of the benefits of pharmacist-managed anticoagulation services has been reported in the literature. The quality and outcomes of anticoagulant clinics run by pharmacists under cooperation agreements in the Middle East have rarely been reported. The first pharmacist-run mobile anti-coagulation clinic in Qatar was inaugurated in March 2013 at Al-Wakrah Hospital. The objectives of this study were: (i) to describe the clinic`s practice model, (ii) to assess clinic quality (i.e. time spent in the therapeutic area (TTR)) and clinical outcomes (i.e. efficacy and safety), and (iii) to determine patient satisfaction and overall quality of life (LQ). IV. IMPLEMENTATION: A. General guidelines for referrals 1.

Patients can be transferred by their UConn healthcare provider to the UConn Health anti-coagulation service at any stage of treatment. 2. All patients must have a written or electronic transfer form for the anticoagulation service (HCH 1810) and a collaborative practice agreement signature form, which has been faxed for verification to 860-676-3446 before being included in the anticoagulation service. 3. The reference provider should contact the anticoagulation service at 860-679-3470 to confirm receipt of the forms. 4. If a patient is deemed unsuitable for treatment by the anticoagulation service, the transfer provider shall be contacted by the anticoagulation specialist within 48 hours of receipt of all required forms. 5.

The provision of anticoagulation by the service begins as soon as the transfer agreement and cooperation forms have been received and accepted by the anticoagulation specialist (72 hours after receipt of the transfer). The transferring physician will provide the following information on or in the patient`s standard transfer form. (Abbreviations: BMP – Basic Metabolic Panel, CBC – Complete Blood Count, LMWH – Basmolecular Heparin): a. Indication of anticoagulation b. Date of initial anticoagulation c. Expected duration of treatment d. Next planned visit to the PCP office e. Information about the family doctor for the desired therapeutic INR area g. Anticoagulant treatments and dose currently prescribed h. INR and prothrombin (PT) time (if applicable) and other relevant laboratory data i.

Artificial heart valve, if applicable j. baseline CBC and BMP for anticoagulants (e.g. B LMWH) k. Medical history of clinically significant bleeding or thromboembolic events l. Past relevant medical history, including current prescribed medications m. Pregnancy test results, if any 6. The doctor will inform the anticoagulant service of any changes in the patient`s treatment regimen. June 2015 Version 1.1 Page 3 References:1. Guyatt G, Akl E, Crowther M, et al. American College of Chest Physicians. Antithrombotic Treatment and Thrombosis Prevention: American College of Chest Physicians Evidence-Based Clinical Practractice Guidelines (9th edition). Chest 2012;141 (2_suppl): 7S-545S.2.

Garcia D, Baglin T, Weitz J, et al. American College of Chest Physicians. Parental anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th edition). Chest circumference 2012;141 (2_suppl): e24S-e43S.3. Ageno W, Gallus A, Wittkowsky A, et al. American College of Chest Physicians. .

Responses are currently closed, but you can trackback from your own site.

Comments are closed.

Subscribe to RSS Feed Follow me on Twitter!